Arbutus Biopharma (ABUS) Misses Q2 EPS by 5c

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.44), $0.05 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Carnival shares drop despite earnings beat on weak guidance
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary